

Kite Pharmaceuticals, Inc. Investor Relations Department 2225 Colorado Ave Santa Monica, CA 90404 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: KITE	
Last Trade:	135.95
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	39.82 - 138.94
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Stock Performance



Press Releases [View all]

Aug 17, 2017

Kite Highlights Publication from the National Cancer
Institute Demonstrating Responses in Patients with
Metastatic Solid Tumors Treated with T Cell Receptor (TCR)
Therapy Targeting MAGE A3

Aug 8, 2017

Kite Reports Second Quarter 2017 Financial Results

Aug 8, 2017

Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma

Aug 7, 2017

<u>Kite Announces Initiation of Axicabtagene Ciloleucel CAR-T</u> <u>Clinical Program in the European Union</u>

Aug 3, 2017

Kite Announces Landmark Study of Refractory Aggressive
Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes
Published in the Journal BLOOD

Financials [View all]

Second Quarter Financial Results

Feb 28, 2017

Annual Report (10-K)

Apr 28, 2017

Proxy Statement (DEF 14A)

Aug 8, 2017

Quarterly Report (10-Q)

May 8, 2017

Quarterly Report (10-Q)

Nov 9, 2016

Quarterly Report (10-Q)